Abstract:To validate the feasibility of using imaging-guided RF hyperthermia (RFH) to enhance intratumorl HSV-TK/Ganciclovir (GCV) suicide gene therapy of ovarian cancers, monitored by optical and ultrasound imaging. Human ovarian cancer cells (SK-OV-3) labeled with luciferase/lentivirus for in vitro confirmation and rats with the same luciferase-positive orthotopic ovarian cancers for in vivo validation were divided into four groups with different treatments: i) combination treatment with intratumoral HSV-TK/GCV-mediated gene therapy plus RFH; ii) gene therapy alone; iii) RFH alone; iv) phosphate buffered saline (PBS). MTS assay and confocal microscopy were used to evaluate the cell viability. Bioluminescence optical and ultrasound imagings were used to monitor the changes of tumor size and bioluminescence signal intensities at different time points (days 0, 7 and 14 posttreatment). The imaging findings were correlated with subsequent pathology confirmation. MTS assay demonstrated the lowest cell proliferation in the group with combination therapy, compared with three control treatments (41.0 ± 6.1% vs 47.8 ± 1.5% vs 97.3 ± 8.5% vs 100%, p<0.01), as corresponded to the smallest number of survived cells by confocal microscopy and the lowest bioluminescence signal by optical imaging. Ultrasound imaging showed the smallest tumor volume with combination therapy, compared with the other three control treatments (0.23 ± 0.19 vs 1.26 ± 0.21 vs 5.43 ± 0.33 vs 6.74 ± 0.36, p<0.05). Bioluminescent optical imaging demonstrated a significantly decreased bioluminescence signal intensity in combination therapy, compared with the other three treatments (0.35 ± 0.12 vs 1.26 ± 0.10 vs 3.43 ± 0.27 vs 3.90 ± 0.12, p<0.05). Both imaging findings were confirmed by pathology, demonstrated as the significantly increased apoptotic cells in the combination therapy group. We have successfully established the "proof-of-principle" of using image-guided intratumoral RFH to enhance HSV-TK/GCV gene therapy of rat ovarian cancers, which may provide a new opportunity for effectively managing ovarian cancers by simultaneous integration of radiofrequency technology, interventional oncology, and direct gene therapy.

Ovarian Cancer Treatment with a Tumor-Targeting and Gene Expression-Controllable Lipoplex

Anti-EGF Antibody Cationic Polymeric Liposomes for Delivery of the P53 Gene for Ovarian Carcinoma Therapy

Epithelial Ovarian Cancer: Feasibility of Image-Guided Intratumoral Radiofrequency Hyperthermia-Enhanced Direct Gene Therapy

Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor α

Abstract No. 576 Orthotopic Ovarian Cancer: Molecular Imaging-Monitored Radiofrequency Hyperthermia-Enhanced Intratumoral Herpes Simplex Virus-Thymidine Kinase (HSV-TK) Gene Therapy

Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts

Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.

In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9

Experimental Therapy Against Ovarian Cancer by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Gene Driven by Human Telomerase Reverse Transcriptase (htert) Promoter

Abstract# 3787: A novel hTERT promoter driven E1A therapeutic for ovarian cancer

Anti-Tumor Study of Posp1-Hsvtk Gene Therapy by Polyethylenimine Mediated Transfection in Ovarian Cancer

A Novel Htert Promoter-Driven E1a Therapeutic for Ovarian Cancer

A Novel Estrogen-Targeted PEGylated Liposome Co-Delivery Oxaliplatin and Paclitaxel for the Treatment of Ovarian Cancer

Transcriptional Control of the MUC16 Promoter Facilitates Follicle-Stimulating Hormone Peptide-Conjugated Shrna Nanoparticle-Mediated Inhibition of Ovarian Carcinoma in Vivo

Follicle Stimulating Hormone Receptor Mediated Gene Delivery to Target Ovarian Carcinoma in Vitro

Efficient Inhibition of Intraperitoneal Human Ovarian Cancer Growth and Prolonged Survival by Gene Transfer of Vesicular Stomatitis Virus Matrix Protein in Nude Mice.

Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy

The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice

Liposomal Delivery of MicroRNA-7 Targeting EGFR to Inhibit the Growth, Invasion, and Migration of Ovarian Cancer.

Administration of PLGA Nanoparticles Carrying Shrna Against Focal Adhesion Kinase and CD44 Results in Enhanced Antitumor Effects Against Ovarian Cancer

Specific Cell Targeting with APRPG Conjugated PEG–PLGA Nanoparticles for Treating Ovarian Cancer